AJP - Lung Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol 295: L1-L15, 2008. First published May 2, 2008; doi:10.1152/ajplung.90200.2008 Free Article
1040-0605/08 $8.00
This Article
Free upon publication Free Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/1/L1    most recent
90200.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Wright, J. L.
Right arrow Articles by Churg, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, J. L.
Right arrow Articles by Churg, A.

INVITED REVIEW

ANIMAL MODELS OF HUMAN LUNG DISEASE

Animal models of chronic obstructive pulmonary disease

Joanne L. Wright,1 Manuel Cosio,2 and Andrew Churg1

1Department of Pathology, University of British Columbia, Vancouver, British Columbia; and 2Respiratory Division, Royal Victoria Hospital, and Meakins-Christie Laboratories, McGill University, Montreal, Quebec, Canada


    ABSTRACT
 TOP
 ABSTRACT
 GRANTS
 REFERENCES
 
The mechanisms involved in the genesis of chronic obstructive pulmonary disease (COPD) are poorly defined. This area is complicated and difficult to model because COPD consists of four separate anatomic lesions (emphysema, small airway remodeling, pulmonary hypertension, and chronic bronchitis) and a functional lesion, acute exacerbation; moreover, the disease in humans develops over decades. This review discusses the various animal models that have been used to attempt to recreate human COPD and the advantages and disadvantages of each. None of the models reproduces the exact changes seen in humans, but cigarette smoke-induced disease appears to come the closest, and genetically modified animals also, in some instances, shed light on processes that appear to play a role.

chronic obstructive pulmonary disease


CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) is an increasingly important cause of morbidity and mortality. COPD is now the fifth leading cause of death worldwide (109), and recent estimates suggest that the prevalence is as high as 9–10% of adults over age 40 (38, 131). In the developed world, cigarette smoking is by far the most important risk factor for COPD. Exposure to air pollution particles, occupational exposures to dusts and fumes (39), and, in the developing world, exposure to biomass fuels used for cooking is also believed to be etiological agents of COPD (38).

There are few animal models of COPD related to air pollution particles, dusts and fumes, and biomass fuels; most COPD models have either used cigarette smoke or other approaches, including genetic modifications to mice, believed to reproduce some of the mechanisms behind cigarette smoke. We have recently reviewed mechanistic studies of smoke-exposed animal models (16). In this paper, we will focus on the pros and cons of different COPD animal models.

The first question to ask in this context is what would constitute a perfect model of human COPD. This is not a simple question because human COPD consists of at least four anatomic lesions (further defined below): emphysema, small airway remodeling (including goblet cell metaplasia), chronic bronchitis, and pulmonary hypertension; a given patient may have any or all of these lesions. In addition, COPD patients may develop acute exacerbations that are believed to have an infectious basis. To further complicate matters, no matter which lesions are present, COPD develops and is slowly progressive over many years.

Because COPD is closely related to the underlying anatomy of the lung, a good animal model should have pulmonary anatomy similar to that of humans. The fundamental mechanisms behind COPD should be similar in animal models and humans. The ideal model would allow the investigator to produce the various different anatomic lesions just listed, all in a short period of time. Unfortunately, all of the known animal models meet only some of the above criteria, and even another human would probably not meet all of them, because, as noted above, there is considerable human to human variation in the pattern of COPD.

A variety of different approaches have been used to attempt to model COPD in animals, but there are some more general principles that will affect any COPD model, namely, 1) considerable differences among species in lung development and maturation; 2) differences among species in lung anatomy; and 3) susceptibility to injurious agents among species and strains within a species (discussed in Ref. 16).

Comparative Anatomy

Development and maturation. The timing of pre- and postnatal development and maturation of the lung varies widely between species, and this problem needs to be taken into account when planning the initial exposure to any injurious agents.

The rat and mouse have no true alveoli at birth and develop all of their alveoli postnatally, with the majority of alveologenesis taking place between days 4 and 14 (90), whereas guinea pigs are well alveolated at birth and have only a small increase in numbers of alveoli as they age. Air space size normally increases with age, but this also varies with species. For example, guinea pigs (155) and rats (56, 96) have a progressive increase in size until 12 and 18 mo [although there appears to be some differences between strains (56)], and hamsters attain maximum size by 6 wk (reviewed in Ref. 61). Air space size change also varies among mouse strains, with BALB/c mice demonstrating increasing size up to 19 mo (61), whereas strain 129 has constant size after 4 wk (97).

The importance of recognizing lung maturation and growth patterns cannot be overstated. Administration of an injurious agent in the immediate postnatal period can interfere with alveolarization, and the enlarged air spaces may be falsely interpreted as emphysema. This is also true of genetically modified animals where the modification itself alters lung development in such a way that the animal has larger than normal air spaces (see Genetic and Genetically Modified Models of COPD).

Anatomic structure: bronchial tree. The various animal species commonly used to model COPD differ significantly from each other and from humans in anatomy of the bronchial tree. Mice and rats have less extensive airway branching than do humans (93). Rodents do not normally have respiratory bronchioles; rather, a respiratory bronchiole-like type of metaplasia is induced by reaction to injury (112). This is considerably different from humans, where there are several generations of membranous and respiratory bronchioles. In humans, the membranous, and to a lesser extent, the respiratory bronchioles, are the targets of smoke-induced small airway remodeling, whereas the respiratory bronchioles are the initial site of injury in centrilobular emphysema.

Anatomic structure: airway epithelium. In humans, the tracheal epithelium is pseudostratified and changes to a simple epithelial type in the subsegmental bronchi (55). The majority of the cells are ciliated and are present throughout the bronchial tree, gradually decreasing in proportion, but extending into the respiratory bronchioles (99). Goblet cells are plentiful in the large airways and progressively decrease until they are rare in the terminal bronchioles (99). This pattern is recapitulated in the guinea pig (Fig. 1) (55).


Figure 1
View larger version (81K):
[in this window]
[in a new window]

 
Fig. 1. Comparison of tracheal epithelium from humans (A), guinea pigs (B), rats (C), and mice (D). In the human there are large numbers of ciliated cells and goblet cells, a pattern that is also found in the guinea pig. The rat has scant goblet cells, and the mouse has none. Ciliated cells are common in the rat but are present only in clusters (arrows) in the mouse. Bar = 100 µm; hematoxylin and eosin (H&E) stain.

 
Rats and mice tend to have ~10-fold greater numbers of nonciliated bronchiolar cells in the small airways compared with humans (113, 166), and the cells vary ultrastructurally among species (113, 114). The tracheal epithelium of the mouse is a single columnar layer, whereas in the rat, the transition between pseudostratified and simple epithelium occurs at the hilum of the lung. In the mouse, goblet cells are rare in the trachea and almost totally absent in the membranous bronchioles; the majority of the tracheal epithelial cells are nonciliated Clara-like cells (105), although ciliated cells occur in large patches and account for ~37% of the total cells (104). In the rat, the proportion of ciliated cells to nonciliated cells increases from upper trachea to bronchioles where they form ~65% of total cells (55). Only a few goblet cells are present in the trachea and large airways and are generally not seen in the small airways.

Anatomic structure: bronchial glands. Interestingly, this appears to be an area of controversy, and this issue is important, since human chronic bronchitis is characterized by hypertrophied and hyperplasic bronchial glands and excess mucus secretion. Although most authors agree that the size of the bronchial glands in laboratory animals is smaller than in humans, there is disagreement as to the number and positioning of glands in the various species (32, 54, 152) (Fig. 2). Despite these differences of opinion, it seems clear that bronchial glands are absent in the mouse and rabbit, almost absent in the hamster, present in the rat but concentrated in the upper portion of the trachea, and irregularly distributed in the guinea pig. Even when present, the number of glands in small animals is markedly less than large mammals, thus making small animals a very poor model for diseases such as chronic bronchitis.


Figure 2
View larger version (111K):
[in this window]
[in a new window]

 
Fig. 2. Comparison of bronchial glands between human (A) and guinea pig (B). The human gland is large and well formed, whereas the guinea pig gland consists of a few acini only. Bar = 200 µm. H&E and alcian blue stain, respectively.

 
Anatomic structure: pulmonary arteries and veins. In humans, the arterial and venous vasculature have definite courses and are separate from each other: the arteries follow the path of the airways, whereas the veins are present in the interlobular septa (Fig. 3). The main pulmonary artery and vessels larger than 1,000 µm in diameter are elastic in nature with short, branching, elastic fibrils arranged in laminae. Vessels between 500 and 100 µm are muscularized, with a tunica media present between two elastic laminae. Muscle becomes less apparent with decreasing size as the spiral of muscle becomes increasing separated until it disappears at the level of the distal arterioles. Pulmonary venules have a single elastic lamina and gradually acquire a muscular layer, the borders of which are generally ill defined as it also contains irregular elastic fibrils. At the level of the atrium, there may be a few cardiac muscle fibers.


Figure 3
View larger version (123K):
[in this window]
[in a new window]

 
Fig. 3. A lung lobule in a human. Note the venous septa that bound the lobule (arrows) and the airway-artery unit in the center of the lobule. Lobules are not found in rodents. Bar = 1,000 µm; H&E stain.

 
In the rat, guinea pig, and mouse, interlobular septa are absent (94). The pulmonary artery branches follow the airways, but the pulmonary vein is independent and follows a separate course from the periphery of the lung to the hilum. The main and large pulmonary arteries are muscular rather than elastic, but there is a similar branching pattern and vessel distribution to that found in the human (45). In the guinea pig (94), the walls of the small arteries have intermittent areas of increased muscular thickness. In rodents, there is a wide variation in the point at which the arterial branches change from muscular to nonmuscular, with ~50% of vessels adjacent to the terminal bronchioles and 80% of vessels adjacent to the alveolar ducts being nonmuscular (45). The arteries have a dense mesh of {alpha}-smooth muscle actin immunopositive cells which is organized in a spiral until the most distal vessels (106). Unlike humans, rodent pulmonary veins have a large amount of cardiac muscle at the hilum of the lung (106), and this is accompanied by a loose mesh of {alpha}-smooth muscle actin immunopositive cells, which decreases as the veins become smaller.

Anatomic structure: bronchial arteries. The bronchial arterial supply is known to be important in the overall lung reaction to injury, and thus anatomy and distribution are important in any animal model. There is considerable person-to-person variation in the human bronchial artery supply (99, 135). These arteries invest the bronchi and extend throughout the length of the bronchial tree, with communication between the bronchial and pulmonary circulations in the terminal respiratory unit. In mice (116), a bronchial artery supply exists, and there are interconnections between the two vascular systems at the level of the capillaries. Rats have a relatively similar system to humans, but with slightly different vascular derivations (135).

Lung Mechanics

A careful quantification of air space size utilizing morphometry should be mandatory to define "emphysema" as a first step to assess the response to the exposure or manipulation used in the intended animal model. However, as noted by Henson and Vandivier (44), it is remarkably easy to induce alveolar enlargement with a very wide variety of manipulations in the mouse, the most widely used animal as a model for emphysema, and this raises the question of how specific such findings might be, particularly since many such manipulations appear to be interfering with lung growth or producing abnormal lung development (see Elastase Emphysema Model and Genetic and Genetically Modified Models of COPD).

Another approach is to use pulmonary function to define emphysema on the basis that, while pulmonary function tests are less sensitive than morphometry and thus may detect only more severe degrees of airways remodeling or parenchymal destruction, they demonstrate meaningful physiological changes. Although mild emphysema may have normal lung mechanics, more marked emphysematous lung destruction ought to have abnormal lung mechanics. The most specific function test representative of emphysema is loss of elastic recoil, determined from pressure-volume (P-V) curves (increased compliance or decreased elastance).

This issue is nicely illustrated in the following papers. Foronjy et al. (25) found that long-term cigarette smoke exposure in two strains of mice (CBA/JXC57BL/GJ) and A/J resulted in a 17% and 32% increase in mean linear intercept (Lm), but no change in lung compliance. Furthermore, neither strain had a decrease in lung elastin by immunostaining or by elastin assay methods. In contrast, Cavarra et al. (14) and Takubo et al. (137) found that the pallid mouse, a strain with low levels of {alpha}1-antitrypsin, developed significant air space enlargement, had a 19% decrease in lung elastin content, and significant increases in compliance (Fig. 4), thus more closely resembling human emphysema. Similar results have been found by us in the AKR/J mouse strain (36) and in the guinea pig (18, 155).


Figure 4
View larger version (25K):
[in this window]
[in a new window]

 
Fig. 4. A: partial pressure-volume (P-V) curves between 3 and 9 cmH2O pressure in the NZW Lac/J (resistant strain), C57 BL6/J (moderately susceptible strain), and AKR/J (super-susceptible strain). [From Takubo et al. (137).] Pallid P-V curves have been added to illustrate the susceptible strain from our prior publication. SJ/L and A/J curves were superimposable to the C57BL/6/J P-V curves. *P < 0.001; **P < 0.0001. B: P-V curves in an emphysematous mouse (A) and a control (B). Curves were done in the traditional way inflating the lung to 30 cmH2O and measuring pressure at the airway opening. The maneuver was done both in step-wise, no flow, and slow deflation methods. Both curves are superimposable. The Flexivent machine was used.

 
Which of these approaches is "correct"? There is no simple answer to this question; at the present time, there are no definitive studies that illustrate a direct correlation of air space enlargement and compliance or a level of air space enlargement beyond which alterations of compliance would be expected, and it is unclear whether more marked emphysema (as defined in this way) is a better approximation to human disease mechanisms than less marked emphysema. Furthermore, the marked laboratory-to-laboratory variations in response in even the same (notional) mouse strains make comparisons almost impossible.

As a general rule, the greater the severity of emphysema, the greater the chance that a protective intervention is really significant, rather than just a minor experiment-to-experiment variation, but this idea must be tempered by the realization that none of these models translates to human disease in any direct fashion, and an intervention that ameliorates fairly mild emphysema might turn out to be mechanistically important. For example, there is increasing evidence for the importance of immunological reactions in the genesis of emphysema (1). In their investigations relating to the role of CD4 and CD8 T-lymphocytes in cigarette smoke-induced emphysema, Maeno et al. (81) found a 19–21% increase in air space size in wild-type C57/Bl/6J mice with a respective increase of 19% and 0.4% in CD4–/– and CD8–/– cell-deficient mice. One must ask, therefore, whether the lack of lung mechanics invalidates the importance of this mechanistic data.

Normally lung mechanics in mice and other rodents are performed at the end of the experiment with the animal alive, anesthetized, paralyzed, and with the chest opened or closed. Mechanics measurements done in dead animals are not as accurate or reproducible, and measurements deteriorate as times from death increase. Lung mechanics and other pulmonary function tests can be easily measured in guinea pigs (155) or other large rodents utilizing a body plethysmograph, a tracheal canula, and an esophageal tube to obtain P-V curves, FRC, and other lung volumes. Flows can also be measured by rapidly deflating the lungs from TLC applying an airway pressure of –50 cmH2O. Measurement of lung mechanics can also be performed in mice, although it is technically more difficult, and we and others have used a small animal ventilator, Flexivent Scireq (Montreal, Canada), equipped with the necessary hardware and software to accurately measure elastance, resistance, and tissue resistance along with inspiratory and expiratory P-V curves.

Lung mechanics can also be measured in live rodents, including mice, with the expectation of recovery after the measurements (nonterminal event). After anesthesia, the animals can be (relatively) easily intubated and subsequent measurements obtained (11, 140). The obvious advantage of this technique is that it allows the documentation of functional changes over time in the same animal (161).

Vendors

There are large numbers of animal suppliers available in North America, Europe, and Asia; regular strains, transgenics, genetic models, etc., are available through these suppliers. The web site www.rodentia.com is a useful and informative starting point where most of the best suppliers of mice are listed with their www portals. It should be kept in mind that at least for the "regular" nonmodified strains of mice, differences in response to specific manipulations in the same strain from different suppliers may occur. In one of our laboratories (M. Cosio), we have identified changes in response to a manipulation (cigarette smoke) in the same strain from the same provider, after a colony had to be restarted from frozen embryos.

Cigarette Smoke Exposure Model of COPD

Given its position as the predominant cause of COPD, animal models using smoke exposure would appear to be the logical choice for investigation, but it is only relatively recently that such models have been created. We have recently reviewed the findings and conclusions from smoke-induced animal models of COPD (16); here we will consider only the advantages and limitations of such models.

Methods of smoke exposure. There are a variety of commercial and home-built smoking machines that have been used with animal models; some systems use nose-only exposures and some whole body exposures. There is a theoretic negative to whole body exposure in that the animals may ingest nicotine or tar substances when cleaning their fur. However, Mauderly et al. (92) showed that although this was a factor, there was less carboxyhemoglobin in the animals given whole body exposure, and these animals had less weight loss than did animals given a nose-only continuous or intermittent types of exposure.

When establishing any smoke exposure model, measurement of either serum cotinine (a nicotine metabolite) or blood carboxyhemoglobin (COHb) is useful as a method of confirming the relative amount of smoke exposure. In our guinea pig nose-only exposure model, we find an acute post-smoke carboxyhemoglobin of 15–20% and a chronic blood carboxyhemoglobin level of ~5%, the latter comparable to that seen in many human smokers. In humans, the dissociation of carboxyhemoglobin when breathing air results in a half-life of ~4–6 h; animal data are not available, although COHb levels rapidly decline after smoke cessation (43). A serum cotinine level of 200–250 ng/ml is equivalent to a mild to moderate human cigarette smoker (31, 43, 103, 127).

Choice and limitation of species. All modern studies of cigarette smoke-induced COPD have used small laboratory animals including mice, rats, and guinea pigs. Guinea pigs offer numerous advantages, including easily recognizable emphysema, more marked small airway remodeling than mice, and the development of considerable goblet cell metaplasia in the airways. Mice and rats develop only minimal goblet cell metaplasia in the smaller airways, although rats do demonstrate metaplasia in the larger airways. As well, it is easy to perform extensive pulmonary function evaluations along with cardiac catheterization in guinea pigs (155, 162). Their main disadvantages are cost, the lack of tools for performing molecular studies, and the limited number of commercial antibodies that cross react with guinea pig proteins.

In our experience, rats are a poor model for COPD. In most investigators' hands, they develop minimal disease, or, if smoked too heavily, develop nonspecific particle overload effects (see, for example, Ref. 132).

Most recent models of COPD have used mice. Detailed pulmonary function is technically difficult, although possible, in mice (36, 84, 137), but P-V curves and compliance changes can be measured fairly easily. Mice offer the advantages of low cost, extensive gene/protein sequence/antibody availability, and, most important, the availability of numerous naturally occurring mouse strains with different reactions to smoke and the ability to produce animals with genetic modifications that shed light on specific processes within COPD.

One point that confounds all of the literature on cigarette smoke-induced models is laboratory-to-laboratory variations in response. Even when the same mouse strain is used, different laboratories get quite different degrees of disease. For example, Churg et al. found increases in mean air space size (Lm) of 37% (20) and 38% (19) after 6 mo of exposure using C57Bl/6 mice, but Cavarra et al. (14) and Guerassimov et al. (36) reported increases of only 14% and 13% in the same strain. In part, this problem is caused by differences in the strains from different providers, technical differences in morphometric techniques, the use of different smoking systems (nose only vs. whole body, smoke concentration, smoke time, and frequency), and by differences in the types of cigarettes smoked. It is our impression that currently available cigarettes (such as Kentucky 2R4F or 2R5F) cause considerably less emphysema than older ones (such as Kentucky 1R1 or 2R1), and this is a serious problem, both in terms of producing disease and particularly in terms of examining interventions, since one never knows whether interventions that ameliorate small increases in air space size would really be effective with more severe disease.

Cigarette smoke-induced models of emphysema. Emphysema is the anatomic lesion that, historically, has attracted the most attention in patients with COPD, and, similarly, has been the focus of most animal models (Figs. 5, 6). Except for {alpha}1-antitrypsin-deficient pallid mice (14, 137), models of smoke-induced emphysema typically produce dilated alveolar ducts; these changes progress with increasing amount of smoking and are, anatomically, similar to a mild form of the centrilobular emphysema commonly found in human cigarette smokers, but the overt tissue destruction seen in humans is much harder to demonstrate in animals (14). The parenchyma between the dilated alveolar ducts is abnormal, with increases in size and number of the pores of Kohn that connect adjacent alveoli (154), a phenomenon also found in the lungs of human cigarette smokers (21, 65, 101). There is evidence that women are more susceptible to the effects of smoke than men (29, 70, 85, 148) and female A/J mice develop emphysema earlier than male A/J mice (84).


Figure 5
View larger version (86K):
[in this window]
[in a new window]

 
Fig. 5. Example of centriacinar emphysema in a human. Note that the respiratory bronchiole and alveolar duct complex is distorted and destroyed. Aggregates of pigmented alveolar macrophages can be found (arrow). Bar = 1,000 µm; H&E stain.

 

Figure 6
View larger version (84K):
[in this window]
[in a new window]

 
Fig. 6. Example of a guinea pig emphysema model induced by exposure to cigarette smoke for 6 mo. A shows a representative control lung, whereas B shows a representative smoke-exposed lung with an overall increase in air space size of ~43%. Bar = 200 µm; H&E stain.

 
The lesions produced in laboratory animals can be subtle, even on microscopic examination; thus morphometric analysis is required to assess the degree of damage. Measurements of air space size (Lm) or surface-to-volume ratio (Sv) (reviewed in Ref. 141) and sometimes destructive index (14) are used for this purpose. Arguably, it would be better to measure only alveolar ducts, since that is the major site of the abnormality, and such measurements do provide more marked differences between smoke-exposed and control animals (see Ref. 19, for example). However, measurements of alveolar duct air require greater morphometric effort (137) and are not widely used.

Smoke-exposed guinea pigs and mice show physiological changes that mimic mild COPD in humans (18, 36, 84, 137, 155). The residual volume increases as does functional residual capacity and total lung capacity. The P-V curve is shifted upwards and to the left, compliance increases, and the flow volume curve demonstrates diminished flow at the lower lung volumes. Ratios of FEV/FVC also decrease. These abnormalities progress with increasing length of smoke exposure (155).

Cigarette smoke-induced small airway remodeling. Small airway remodeling (increased matrix components, inflammatory cells, and goblet cell metaplasia in the airway wall with luminal narrowing, distortion, and obstruction by mucus) is now accepted as an important cause of airflow obstruction in human smokers (46, 47, 98, 107, 156). These changes increase with increasing Global Initiative on Chronic Obstructive Lung Disease (GOLD) stage (47). Excess mucus secretion is also thought to be important in the pathogenesis of acute exacerbations of COPD (reviewed in Ref. 6).

In animals, early smoke inhalation studies demonstrated increases in the numbers of goblet cells in the proximal trachea in a variety of species (7, 42, 57, 69, 108, 117), but there is a considerable species effect and a large degree of variation in the degree of metaplastic change. In the guinea pig model, chronic smoke exposure induces secretory cell metaplasia in the small airways (158), and similar to humans, smoking cessation reduces the degree of metaplasia (160).

Little attention has been paid to small airway wall remodeling in animal models, probably because these changes are too subtle to be reliably picked up by casual microscopic observation, and some deny their existence (84). Nonetheless, morphometric analysis confirms that the small airway walls are thickened in both mice and guinea pigs after long-term smoke exposure (10, 17, 18, 159). Most of the increased wall area is composed of collagen and fibronectin, and smooth muscle is not increased (10, 17, 95, 159). There is also increased collagen fiber alignment and more dense packing of the fibers, findings that imply increased mechanical stiffness in the airway wall (159). In guinea pigs, the severity of changes in collagen structure correlates negatively with PEF and FEV0.1/FVC, and positively with airway resistance. Physiological lung volumes correlate with air space size, but RV and TLC also are related to airway wall thickness (159).

Small numbers of lymphocytes are found around the bronchioles in mice and guinea pigs and are analogous to the lymphoid aggregates seen in humans. Smoke causes quite marked increases in the number and size of these aggregates (9, 10, 146).

Cigarette smoke-induced vascular remodeling and pulmonary hypertension. In subjects with established pulmonary hypertension related to COPD, there is intimal thickening and muscular hyperplasia in the normally muscularized vessels adjacent to the bronchioles and increased muscularization of the usually partially muscularized arteries adjacent to the alveolar ducts (reviewed in Refs. 3, 157).

In Hartley strain guinea pigs, chronic cigarette smoke exposure produces about a 25% increase in pulmonary arterial pressure (160, 162), which, interestingly, appears after 1 mo of smoke exposure and does not progress. Similar to human disease, PHT in guinea pigs is associated with muscularization of the small, normally poorly muscularized pulmonary arteries adjacent to the alveolar ducts (162). Increased pulmonary artery pressure (~30%) has also been reported in one study of smoke-exposed rats (72) but thus far has not been reported in mice. Vascular remodeling, however, has been reported in mice, and there are apparent strain differences in the severity of remodeling (100).

Conclusions regarding smoke-induced models. Cigarette smoke exposure to animals appears to be the best approximation to human COPD: a form of emphysema, small airway remodeling, and pulmonary hypertension can be produced (Table 1). Mucus hypersecretion is more problematic. One important downside to these models is that production of either emphysema or small airway remodeling takes months of smoke exposure (usually on the order of 6 mo) and thus is an expensive and time-consuming proposition. However, the most important limitation of smoke models, no matter what species is selected and no matter how long animals are smoked, is that the disease they produce is mild, probably equivalent to human GOLD (24, 115) stage 1 or 2 disease. In humans, the majority of morbidity and mortality occurs in patients with GOLD stage 3 or 4 disease (FEV1 <50% predicted), but the type of severe emphysema or severe small airway remodeling found in GOLD stage 3 or 4 patients simply cannot be reproduced in animals using smoke exposure. Last, in advanced GOLD stage patients, COPD frequently progresses even after the patient stops smoking, but this phenomenon has not been reproduced in animal models, where cessation of smoke exposure leaves the animals with stable, nonprogressive emphysema, and goblet cell metasplasia regresses (160).


View this table:
[in this window]
[in a new window]

 
Table 1. Pros and cons of cigarette smoke-induced model of COPD

 
Apoptosis as a Model of COPD

There are several excellent recent reviews of this subject (144, 145, 151, 163). The idea that emphysema occurs as a failure of the lung maintenance and repair system follows from studies that have induced apoptosis by interference with vascular endothelial growth factor (VEGF) (60) or its receptor (VEGF-R) (139) or the VEGF-VEGFR complex (88). Apoptosis generally involves activation of the caspase cascade and can be induced by intratracheal instillation of activated caspase-3 as well as other agents (2). Activation of ceramide, an upstream regulator, (111) will also induce apoptosis.

These models induce air space enlargement in a very short period of time (Fig. 7) but do not appear to affect the airways. Inhibition of VEGF receptors sufficient to induce air space enlargement also causes pruning of the vascular bed and pulmonary hypertension (60, 138, 143, 150), with increased muscularization of the small pulmonary arteries.


Figure 7
View larger version (58K):
[in this window]
[in a new window]

 
Fig. 7. Example of a mouse apoptosis emphysema model induced by installation of active caspase-3. A shows a representative control lung. B shows a representative image from lungs 48 h after installation of active caspase-3, with an overall increase in air space size of ~4%. The arrowheads indicate enlarged air spaces. Bar = 50 µm; H&E stain. [From Petrache et al. (110).]

 
Conclusions. Although inhibition of the VEGF system appears to result in relatively permanent air space enlargement, instillation of a single dose of activated caspase-3 produced initial air space enlargement followed by diminution of air space size within 15 days (2). Thus far, none of these models has been shown to be associated with matrix breakdown, an event that is believed to be central to the pathogenesis of emphysema (reviewed in Ref. 16), nor have they been shown to reproduce the physiological changes of emphysema. Finally, it is important to recognize that apoptosis has only been found to be increased in human lungs with severe emphysema, and analysis of the smoke-exposed mouse or guinea model has shown inconsistent results, with no significant increases in the number of apoptotic cells in some studies (Churg A and Wright JL, unpublished data) (25), whereas one study found focal areas of apoptosis, but only in DBA/2 and not in C57Bl/6 mice (5) (Table 2).


View this table:
[in this window]
[in a new window]

 
Table 2. Pros and cons of apoptosis model of COPD

 
Elastase Emphysema Model

The current generally accepted hypothesis of cigarette smoke-induced emphysema is the protease-antiprotease hypothesis. This hypothesis developed out of two key observations: first, Laurell and Eriksson (71) reported that patients who were deficient in {alpha}1-antitrypsin developed early emphysema. Second, in 1965, Gross et al. (34) described the induction of emphysema in rats by instillation of the plant protease, papain. These observations led to the idea that emphysema develops as a result of a cigarette smoke-mediated influx of inflammatory cells into the lower respiratory tract with resulting release of proteases that destroy the parenchymal matrix.

The protease-antiprotease hypothesis was in large measure formulated from experiments in which emphysema was caused by administration of elastolytic enzymes, either by intratracheal instillation or aerosol inhalation; these models are currently referred to by the generic term "elastase emphysema" (Fig. 8). A variety of enzymes have been used for this purpose (52, 53, 74, 75), and one of the key findings in this regard was that only enzymes that could degrade intact elastin-produced emphysema; collagenases by themselves were ineffective (75, 136). These findings led to the current belief that destruction of the elastin framework of the lung is the fundamental pathological abnormality in emphysema.


Figure 8
View larger version (35K):
[in this window]
[in a new window]

 
Fig. 8. An example of a murine emphysema model induced by elastase. The figure contrasts a representative control lung to a representative elastase-treated lung, with an overall increase in air space size of ~60%; H&E stain. Photos courtesy of Dr. S. Shapiro, University of Pittsburgh, PA.

 
While papain was used in initial studies, its elastase activity depends on its purity and source (75). Almost all recent studies have used either porcine pancreatic elastase (PPE) or human neutrophil elastase (HNE). PPE offers the advantages of being inexpensive and easy to obtain. Consistent quality human neutrophil elastase is now available but considerably more expensive. Experiments using crude preparations of human neutrophils first and then purified HNE were in fact instrumental in arriving at the notion that smoke-evoked inflammatory cells release elastolytic proteases that can destroy the lung (52, 53, 75). From a practical point of view, it is important to note that PPE and HNE do not have the same proteolytic spectrum; they have different primary endogenous inhibitors [{alpha}1-antitrypsin for HNE, but {alpha}2-macroglobulin for PPE, although {alpha}1-antitrypsin is also effective (133)], and, even more important, a particular exogenous inhibitor may not inhibit both of these enzymes (for example, see Refs. 67 and 68 and see below). This is a crucial point to bear in mind if one is attempting to show efficacy of a novel inhibitor.

A wide variety of animals have been used in the elastase emphysema model (52, 75). Much of the early work, and some recent work, was done in hamsters, based initially on the empiric observation that hamsters appeared to develop more severe disease. The reason for this turns out to be that hamsters normally have relatively low levels of {alpha}1-antitrypsin (52, 75). Conversely, several investigators showed that administration of {alpha}1-antitrypsin or normal serum but not serum from persons deficient in {alpha}1-antitrypsin prevented or ameliorated elastase emphysema (58, 86); this observation again was important in formulating the protease-antiprotease hypothesis.

Table 3 lists pros and cons of the elastase emphysema model. The major advantages are that emphysema can be rapidly induced by a single treatment with an inexpensive reagent, which makes it vastly cheaper and easy to run than a 6-mo smoke exposure. Disease severity can be controlled by selection of enzyme dose. As opposed to smoke-induced emphysema, it is relatively easy to produce severe emphysema with elastase instillation, and this facilitates detection of pulmonary function abnormalities, particularly when evaluating the effects of an inhibitor or intervention such as lung volume reduction surgery or abnormalities in connective tissue elasticity (15, 51). Biochemical and in situ hybridization studies have shown that over time there is increased synthesis of elastin and to a lesser extent collagen (77), making the model a candidate for studies on alveolar repair and regeneration [however, studies using all trans retinoic acid and/or bone marrow cell instillation or various colony-stimulating factors to attempt to drive repair are contradictory (49, 50, 76, 102, 164)]. But probably the most important current reason to use the elastase emphysema model is the situation where an intervention requires scarce/expensive resources that would not be feasible for a 6-mo smoke exposure. For example, Houghton et al. (48) recently showed that antibodies against elastin fragments ameliorated the inflammatory response and emphysema in mice given PPE.


View this table:
[in this window]
[in a new window]

 
Table 3. Pros and cons of elastase model of COPD

 
The major disadvantages of the elastase emphysema model center around two related problems: 1) although both elastase and cigarette smoke produce emphysema through proteolytic attack on the lung matrix, the detailed mechanisms of this process are probably very different; and 2) the mechanisms behind elastase emphysema are not clear. Both light microscopic and electron microscopic studies (52, 66, 165) show rapid loss of elastin after enzyme instillation, but the disease progresses (depending somewhat on animal and dose) long after elastase activity can no longer be detected. In fact, the measured half-life of HNE or PPE in this model is ~45–50 min (133). It has been suggested that progression is caused by enzyme bound to the matrix and not detectable with conventional assays, but a late intervention (day 20) with an elastase inhibitor did not prevent progression (79), which the authors interpreted to mean that other processes are involved. Single dose elastase inhibitors appear to work when given immediately before or immediately after elastase administration, but are not effective if given 4 or 8 h later (35, 63, 134). However, two synthetic serine elastase inhibitors [ICI 200,800 and ICI 200,855 (153)] prevented both PPE and HNE driven emphysema when started 24 h after enzyme dosing and continued on a daily basis. Other novel elastase inhibitors/elastin protectors (13, 67, 80) also provide some degree of protection.

In fact, the model is certainly more complicated than pure elastase attack. Elastase emphysema itself is subtly different from human emphysema, with pure alveolar enlargement predominating in elastase emphysema and increased alveolar wall destruction (measured by the destructive index) in human (23) and to some extent in murine smoke-induced emphysema (84). Soon after enzyme administration, there is both hemorrhage and an inflammatory exudate which includes neutrophils and macrophages in the lower respiratory tract, and there is upregulation of a variety of proinflammatory mediators such as TNF{alpha}, IL-1β, IL-6, and IL-8 (28). It has been claimed that there are increased numbers of apoptotic parenchymal cells (126, 164), but these studies have only used TUNEL staining and hence are inconclusive. Inflammatory processes clearly play an important role since mice lacking both TNF{alpha} and IL-1 receptors are ~80% protected against PPE-driven emphysema and inflammation (78), as are mice overexpressing CuZnSOD (26) and mice given the anti-inflammatory agent HO-1 by adenoviral transfer (129). Elgin-C, which inhibits rat NE but not PPE, was protective against PPE-driven emphysema, supporting a role for endogenous elastases (68). On the other hand, a broad spectrum MMP inhibitor decreased emphysema but not inflammation (8).

One further practical complication is that animal age appears to be important, but the literature is contradictory, with claims that either younger or older animals are more resistant to PPE (33, 59, 87).

Conclusions regard the elastase emphysema model. Overall, these findings indicate that although elastase emphysema is simple to produce, the model is not mechanistically simple at all. At best, elastase emphysema is a screening technique for mechanisms and/or interventions that could apply to human smokers; however, this approach is fairly far removed from smoke exposure and in our opinion is generally inferior to animal models using smoke exposure.

Starvation-Induced Model of COPD

In humans, chronic malnourishment or actual starvation appears to be associated with emphysema-like alterations of the lung parenchyma (reviewed in Ref. 22). Starvation models in rats have varied in the amount of reduced feeding and also have varying degrees of alteration in lung structure and physiological changes (119, 121125). Alterations of lung mechanics were generally characterized by a decrease in lung volume related to transpulmonary pressures, and in one study (125), the shift in the saline P-V curve was accompanied by significant reductions in elastic recoil, and chord compliance (slope of the straight line between 80 and 40% maximal lung volume) was increased by 47%, with a 53% increase in air space size. Mechanical changes reverted to normal with refeeding (123), and although bulk lung hydroxyproline also reverted to normal, elastin remained decreased (122). Cycles of starvation and refeeding resulted in overall findings similar to those above, but there was also a decreased alveolar surface area interpreted as a decreased number of alveoli (120). Calorie depletion accompanied by protein depletion showed the unexpected finding of less severe emphysema than in those animals with similar caloric intake that included protein. All of the calorie-restricted groups had smaller lung volumes and fewer alveoli than did the control group indicating that the effect of starvation is a lack of lung growth.

A comparison between starvation (45% loss of body wt) and elastase-induced emphysema showed considerable differences between the two models (41). While elastase-induced emphysema mimicked human emphysema, with increased lung volumes and subdivisions of lung volume, a shift to the right of the P-V curve, and reduced expiratory flow rates, the P-V curve in the starvation group was shifted to the right, the lung volumes were not increased, and there was no decrease in airflow. Both groups had enlarged air spaces suggesting that the two models may represent lung destruction in the case of elastase emphysema and alterations of lung growth in the case of starvation emphysema. But recent studies in mice (89, 91) have questioned this explanation since alveoli appear to be lost early in calorie restriction and gained after refeeding. Starvation appears to stimulate caspase gene expression and Fas death receptor expression, with depression of cell replication, while refeeding increases cell replication, DNA synthesis, and increased RNA expression for a large number of cell replication-related genes.

Conclusions regarding starvation models. Starvation models are relatively short term in duration and produce enlarged air spaces, but they do not produce the physiological changes of emphysema and more likely represent models of abnormal lung growth or abnormal repair (Table 4). No airway or vascular alterations have been described.


View this table:
[in this window]
[in a new window]

 
Table 4. Pros and cons of starvation model of COPD

 
LPS-Induced Models of COPD

LPS is a glycolipid component of gram-negative bacterial cell walls and is used because of its proinflammatory effects. It is present as a contaminant in cigarette smoke, air pollution, and organic dusts. In humans, chronic exposure to LPS-laden dusts results in decreased lung function (reviewed in Ref. 147). In the acute model, LPS induces a mixed inflammatory reaction with increases in neutrophils (8) and increases in BAL TNF{alpha} and IL-1β, and increases in MMP-9 and MMP-12 (73, 147) (Fig. 9A). In mice (147), repeated intratracheal LPS installations induces marked inflammation with predominately CD4+ T cell lymphoid aggregates around the airways and large vessels, and an increase in intra-epithelial bronchiolar epithelial cell lymphocytes. This was associated with large numbers of intra-alveolar macrophages. Cytokine mRNA profiles showed increases in TNF{alpha}, IFN{gamma}, and IL-18, a finding that persisted after exposures ceased.


Figure 9
View larger version (81K):
[in this window]
[in a new window]

 
Fig. 9. A: example of a mouse subacute LPS model induced by exposure to LPS for 1 h per day for 5 days. Note the inflammatory reaction in the air spaces and interstitium. H&E stain. Magnification, ~x10, courtesy of Dr. M. K. Lee, Battelle Science and Technology, Richland, WA. B: example of a hamster emphysema model induced by installation of LPS twice per week for 4 wk and death after 28 days after the final installation. Emphysematous areas are surrounded by relatively normal areas with an overall increase in air space size of ~30%. The arrows point to iron depositions. [From Rudolphus et al. (118).]

 
With chronic administration over several weeks, LPS instillation produces enlarged air spaces (Fig. 9B) and remodeled airways with thickened walls and increased goblet cells in the larger airways in mice, guinea pigs, and rats (40, 142, 147). In the guinea pig model (40), progressive exposures resulted in a decline in specific airway conductance and an increased duration of bronchoconstriction after exposure. These changes resemble human emphysema and small airway remodeling (albeit again relatively mild) and may be driven by mechanisms that are somewhat similar to human disease; however, these mechanisms are poorly defined.

Conclusions regarding LPS models. LPS instillation is a short term model which produces some anatomic features of human COPD, but the inflammatory infiltrate differs from that in smoke models, suggesting different mechanisms (Table 5). Probably the most important use of LPS is to mimic acute exacerbations, either given alone or given to animals also receiving cigarette smoke. The topic of models of acute exacerbation has been recently reviewed in Refs. 30, 62, 83.


View this table:
[in this window]
[in a new window]

 
Table 5. Pros and cons of LPS model of COPD

 
Genetic and Genetically Modified Models of COPD

Much of the recent literature on COPD models has used either naturally occurring mouse strains or laboratory-produced animals that either overexpress or lack particular genes. Several excellent reviews of such models are available (12, 82, 128, 144, 149), and we will only comment briefly here on their advantages and disadvantages.

Different naturally occurring mouse strains show markedly different responses to smoke which depend in part on naturally occurring levels of antioxidant and antiprotease protection and in part on genetic factors that control the innate and acquired inflammatory response to smoke (14, 81). Different strains have a variety of genetic differences, and thus one usually cannot attribute different responses to an insult such as smoke to a single gene change, as is possible with man-made genetically targeted animals (there are exceptions to this rule, however, such as pallid mice that are {alpha}1-antitrypsin deficient) (14, 137).

Genetically altered animals allow investigation of the effects of a specific gene/protein on all of the different anatomic lesions of COPD and potentially also are useful in designing therapeutic agents. Most attention has been directed to models of emphysema, with much less information available about small airway remodeling (64). All such models need to be interpreted very cautiously, because constitutive overexpression or knockout of a particular gene can interfere with lung development and lung growth, resulting in enlarged air spaces that superficially appear to represent emphysema but are really developmental abnormalities. Conversely, constitutive expression of a gene might also lead to accelerated aging, and accelerated senescence mice are known to develop emphysema (130).

Several different approaches have been taken to try and get around the issue of developmental abnormalities. Some constitutive transgenic models of emphysema have concentrated on selection of strains in which transgene expression is present at a very low level and disease only appears to manifest late in adulthood (27). Such models provide support for the importance of the gene in question but by definition cannot rule out either subtle developmental or aging abnormalities.

Inducible models generally use constructs in which feeding of doxycycline drives the gene in question with a lung-specific promoter. This approach in theory prevents problems with developmental or premature aging effects. However, there may be small amounts of "leakage" of the transgene even in the absence of doxycycline, and it has been reported that the reverse tetracycline-transactivator gene that is used to create inducible constructs can itself can produce enlarged air spaces (130). As well, doxycycline is a matrix metalloprotease inhibitor that inhibits MMPs such as MMP-2 and MMP-9 that are thought to play a role in COPD (37). Thus careful controls are essential in interpreting such experiments. Last, it is important to remember that overexpression of a particular gene may lead to production of huge amounts of protein, and there is no guarantee that "pharmacological" doses of a particular protein act in a similar fashion to physiological doses.

Conclusions regarding models using genetically altered animals and different naturally occurring strains. These problems notwithstanding, genetically modified animals and naturally occurring mouse strains have produced a wealth of data, either by themselves or when such animals are exposed to cigarette smoke. We have recently reviewed the topic of smoke-induced models and the mechanisms behind such models in this journal (16). How closely these models mimic the pathogenesis of human disease is still open to question (4).

Conclusions

A variety of quite widely differing types of animal models has been created to attempt to reproduce human COPD. None of them succeeds perfectly in this attempt, and all have problems. Nonetheless, cigarette smoke-induced models of either naturally occurring or man-made animal strains appear to be the best choice for most purposes if one has the resources and patience to carry out the very long exposures required. Elastase emphysema has a limited role, particularly when resources are scarce. Models that examine failure of lung maintenance or failure of repair will probably be important in understanding the pathogenesis of emphysema, but as yet don't clearly approximate events in the human lung.


    GRANTS
 TOP
 ABSTRACT
 GRANTS
 REFERENCES
 
This work was supported by Canadian Institutes of Health Research Grants 42539 and 81409, a grant from the Heart and Stroke Foundation of British Columbia and Yukon, and the Lloyd Carr-Harris Foundation.


    FOOTNOTES
 

Address for reprint requests and other correspondence: J. L. Wright, Dept. of Pathology, Univ. of British Columbia, 2211 Wesbrook Mall, Vancouver, B. C., Canada V6T 2B5 (e-mail: jlwright{at}interchange.ubc.ca)


    REFERENCES
 TOP
 ABSTRACT
 GRANTS
 REFERENCES
 

  1. Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax 58: 832–834, 2003.[Free Full Text]
  2. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 28: 555–562, 2003.[Abstract/Free Full Text]
  3. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 21: 892–905, 2003.[Abstract/Free Full Text]
  4. Barnes PJ. Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 866–867, 2007.[Free Full Text]
  5. Bartalesi B, Cavarra E, Fineschi S, Lucattelli M, Lunghi B, Martorana PA, Lungarella G. Different lung responses to cigarette smoke in two strains of mice sensitive to oxidants. Eur Respir J 25: 15–22, 2005.[Abstract/Free Full Text]
  6. Berge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 21, S41: 46S–53S, 2003.[Abstract/Free Full Text]
  7. Bernfeld P, Homburger F, Soto E, Pai KJ. Cigarette smoke inhalation studies in inbred Syrian Golden hamsters. JNCI 63: 675–689, 1979.[ISI][Medline]
  8. Birrell MA, Wong S, Dekkak A, DeAlba J, Haj-Yahia S, Belvisi MG. Role of matrix metalloproteinases in the inflammatory response in human airway cell-based assays and in rodent models of airway disease. J Pharmacol Exp Ther 318: 741–750, 2006.[Abstract/Free Full Text]
  9. Bracke KR, D'hulst AI, Maes T, Demedts IK, Moerloose KB, Kuziel WA, Joos GF, Brusselle GG. Cigarette smoke-induced pulmonary inflammation, but not airway remodelling, is attenuated in chemokine receptor 5-deficient mice. Clin Exp Allergy 37: 1467–1479, 2007.[ISI][Medline]
  10. Bracke KR, D'hulst AI, Maes T, Moerloose KB, Demedts IK, Lebecque S, Joos GF, Brusselle GG. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol 177: 4350–4359, 2006.[Abstract/Free Full Text]
  11. Brown RH, Walters DM, Greenberg RS, Mitzner W. A method of endotracheal intubation and pulmonary functional assessment for repeated studies in mice. J Appl Physiol 87: 2362–2365, 1999.[Abstract/Free Full Text]
  12. Brusselle GG, Bracke KR, Maes T, D'hulst AI, Moerloose KB, Joos GF, Pauwels RA. Murine models of COPD. Pulm Pharmacol Ther 19: 155–165, 2006.[CrossRef][ISI][Medline]
  13. Cantor JO, Shteyngart B, Cerreta JM, Liu M, Armand G, Turino GM. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc Soc Exp Biol 225: 65–71, 2000.[Abstract/Free Full Text]
  14. Cavarra E, Bartalesi B, Lucattelli M, Fineschi S, Lunghi B, Gambelli F, Ortiz LA, Martorana PA, Lungarella G. Effects of cigarette smoke in mice with different levels of {alpha}1-proteinase inhibitor and sensitivity to oxidants. Am J Respir Crit Care Med 164: 886–890, 2001.[Abstract/Free Full Text]
  15. Chen JC, Brenner M, Kafie FE, Yoong B, Budd M, Gassel A, Waite TA, Millikan J, Huh J, Wang NS, McKenna R, Gelb A, Wilson AF, Bern MW. An animal model for lung volume reduction therapy of pulmonary emphysema. J Invest Surg 11: 129–137, 1998.[ISI][Medline]
  16. Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol 294: L612–L631, 2008.[Abstract/Free Full Text]
  17. Churg A, Tai H, Coulthard T, Wang R, Wright JL. Cigarette smoke drives small airway remodeling by induction of growth factors in the airway wall. Am J Respir Crit Care Med 174: 1327–1334, 2007.[CrossRef][ISI]
  18. Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL. An MMP-9/-12 inhibitor prevents smoke-induced emphysema and small airway remodeling in guinea pigs. Thorax 62: 706–713, 2007.[Abstract/Free Full Text]
  19. Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. Tumor necrosis factor-{alpha} drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 170: 492–498, 2004.[Abstract/Free Full Text]
  20. Churg A, Wang X, Wang R, Meixner SC, Pryzdail EL, Wright JL. Alpha-1-antitrypsin suppresses TNF alpha and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol 37: 144–151, 2007.[Abstract/Free Full Text]
  21. Cosio MG, Shiner RJ, Saetta M, Wang NS, King M, Ghezzo H, Angus E. Alveolar fenestrae in smokers. Am Rev Respir Dis 133: 126–131, 1986.[ISI][Medline]
  22. Coxson HO, Chan IHT, Mayo JR, Hlynsky J, Nakano Y, Birmingham CL. Early emphysema in patients with anorexia nervosa. Am J Respir Crit Care Med 170: 748–752, 2004.[Abstract/Free Full Text]
  23. Eidelman DH, Bellofiore S, Chiche D, Cosio MG, Martin JG. Behavior of morphometric indices in pancreatic elastase-induced emphysema in rats. Lung 168: 159–169, 1990.[Medline]
  24. Fabbri L, Pauwels RA, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary updated 2003. COPD 1: 105–141, 2003.
  25. Foronjy RF, Mercer BA, Maxfield MW, Powell CA, D'Armiento J. Structural emphysema does not correlate with lung compliance: lessons from the mouse smoking model. Exp Lung Res 31: 547–562, 2005.[CrossRef][ISI][Medline]
  26. Foronjy RF, Mirochnitchenko O, Propokenko A, Lemaitre V, Jia Y, Inouye M, Okada Y, D'Armiento J. Superoxide dismutase expression attenuates cigarette smoke- or elastase-generated emphysema in mice. Am J Respir Crit Care Med 173: 623–631, 2006.[Abstract/Free Full Text]
  27. Foronjy RF, Okada Y, Cole R, D'Armiento J. Progressive adult-onset emphysema in transgenic mice expressing human MMP-1 in the lung. J Appl Physiol 284: L727–L737, 2003.
  28. Gamze K, Mehmet HM, Deveci F, Turgut T, Ilhan F, Ozercan I. Effect of bosentan on the production of proinflammatory cytokines in a rat model of emphysema. Exp Mol Med 39: 614–620, 2007.[ISI][Medline]
  29. Gan WQ, Man SF, Postma DS, Camp P, Sin DD. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res 7: 52–61, 2006.[CrossRef][Medline]
  30. Gaschler GJ, Bauer CM, Zavitz CC, Stampfli MR. Animal models of chronic obstructive pulmonary disease exacerbations. Contrib Microbiol 14: 126–141, 2007.[Medline]
  31. Gaworski CL, Dozier MM, Gerhart JM, Rajendran N, Brennecke LH, Aranyi C, Heck JD. 13-Week inhalation toxicity study of menthol cigarette smoke. Food Chem Toxicol 35: 683–692, 1997.[CrossRef][ISI][Medline]
  32. Goco RV, Kress MB, Brantigan OC. Comparison of mucus glands in the tracheobronchial tree of man and animals. Ann NY Acad Sci 106: 555–571, 1963.[CrossRef][ISI][Medline]
  33. Goldstein RH. Response of the aging hamster lung to elastase injury. Am Rev Respir Dis 125: 295–298, 1982.[ISI][Medline]
  34. Gross P, Pfitzer EA, Tolker E, Babyak MA, Kaschak M. Experimental emphysema: its production in normal and silicotic rats. Arch Environ Health 11: 50–58, 1965.[ISI][Medline]
  35. Gudapaty SR, Liener IE, Hoidal JR, Padmanabhan RV, Niewoehner DE, Abel J. The prevention of elastase induced emphysema in hamsters by the intratracheal administration of a synthetic elastase inhibitor bound to albumin microspheres. Am Rev Respir Dis 132: 159–163, 1985.[ISI][Medline]
  36. Guerassimov A, Hoshino M, Takubo Y, Turcotte A, Yamamoto M, Ghezzo H, Triantafillopoulos A, Whittaker K, Hoidal JR, Cosio MG. The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am J Respir Crit Care Med 170: 974–980, 2005.[CrossRef][ISI]
  37. Haas TL, Doyle JL, Distasi MR, Norton LE, Sheridan KM, Unthank JL. Involvement of MMPs in the outward remodeling of collateral mesenteric arteries. Am J Physiol Heart Circ Physiol 293: H2429–H2437, 2007.[Abstract/Free Full Text]
  38. Halbert RJ, Natoli JL, Gano A, Badamqarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28: 523–532, 2006.[Abstract/Free Full Text]
  39. Harber P, Tashkin DP, Simmons M, Crawford L, Hnizdo E, Connett J, Lung Health Study Group. Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176: 994–1000, 2007.[Abstract/Free Full Text]
  40. Harkema JR, Hotchkiss JA. Ozone and endotoxin-induced mucous cell metaplasias in rat airway epithelium: novel animal models to study toxicant-induced epithelial transformation in airways. Toxicol Lett 68: 251–263, 1993.[CrossRef][ISI][Medline]
  41. Harkema JR, Mauderly JL, Gregory RE, Pickrell JA. A comparison of starvation and elastase models of emphysema in the rat. Am Rev Respir Dis 129: 584–591, 1984.[ISI][Medline]
  42. Hayashi M, Sornberger GC, Huber GL. Differential response in the male and female tracheal epithelium following chronic tobacco smoke inhalation. Chest 4: 515–518, 1978.
  43. Heck JD, Gaworski CL, Rajendran N, Morrissey RL. Toxicologic evaluation of humectants added to cigarette tobacco: 13-week smoke inhalation study of glycerin and propylene glycol in Fischer 344 rats. Inhal Toxicol 14: 1135–1152, 2002.[CrossRef][ISI][Medline]
  44. Henson PM, Vandivier RW. The matrix degrades, neutrophils invade. Nature Med 12: 280–281, 2006.[CrossRef][ISI][Medline]
  45. Hislop A, Reid L. Normal structure and dimensions of the pulmonary arteries in the rat. J Anat 125: 71–83, 1978.[ISI][Medline]
  46. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364: 709–721, 2004.[CrossRef][ISI][Medline]
  47. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645–2653, 2004.[Abstract/Free Full Text]
  48. Houghton AM, Quintero PA, Perkins DL, Kobayashi DK, Kelley DG, Marconcini LA, Mecham RP. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 116: 753–759, 2006.[CrossRef][ISI][Medline]
  49. Ishikawa T, Aoshiba K, Yokohori N, Nagai A. Macrophage colony-stimulating factor aggravates rather than regenerates emphysematous lungs in mice. Respiration 73: 538–545, 2006.[CrossRef][ISI][Medline]
  50. Ishizawa K, Kubo H, Yamada M, Kobayashi S, Numasaki M, Ueda S, Suzuki T, Sasaki H. Bone marrow-derived cells contribute to lung regeneration after elastase-induced pulmonary emphysema. FEBS Lett 556: 249–252, 2004.[CrossRef][ISI][Medline]
  51. Ito S, Ingenito EP, Brewer KK, Black LD. Mechanics, nonlinearity, and failure strength of lung tissue in a mouse model of emphysema: possible role of collagen remodeling. J Appl Physiol 98: 503–511, 2005.[Abstract/Free Full Text]
  52. Janoff A. Elastases and emphysema. Am Rev Respir Dis 132: 417–433, 1985.[ISI][Medline]
  53. Janoff A, White R, Carp H, Harel S, Dearing R, Lee D. Lung injury induced by leukocytic proteases. Am J Pathol 97: 111–136, 1979.[Abstract]
  54. Jeffery PK. Morphologic features of airway surface epithelial cells and glands. Am Rev Respir Dis 128: S14–S20, 1983.[ISI][Medline]
  55. Jeffery PK, Reid LM. The respiratory mucous membrane. In: Respiratory Defense Mechanisms Part 1, edited by Brain JD, Proctor DF, and Reid LM. New York: Dekker, 1977, p. 193–245.
  56. Johanson WG, Pierce AK. Lung structure and function with age in normal rats and rats with papain emphysema. J Clin Invest 52: 2921–2927, 1973.[CrossRef][ISI][Medline]
  57. Jones R, Dolduc P, Reid L. Protection of rat bronchial epithelium against tobacco smoke. Br Med J 2: 142–144, 1972.[ISI][Medline]